Within the PREDiCT series, the 3D Tissue Models Summit, stands out as the only industry-focused 3D tissue models summit delving into real-world applications for drug discovery and development and how to leverage such data as part of the regulatory approval package. This summit provides the community not only unparalleled educational opportunities but also to form pre-competitive collaboration.

With the FDA Modernization Act 2.0 passing, newer model types emerging and throughput capacity increasing, the 3D tissue model space is energized to hit another wave of innovation. These have instilled confidence amongst preclinical, translational, and pharmacology scientists which enable increased productivity, improved understanding of vascular biology, more predictive toxicity of the disease model, but also opening the doors for standardizing model characterization, biomarker discovery and treatment guidance for precision medicine in the future – all of which would complement animal model data to enhance clinical translatability for candidate success.

The 8th annual event will return to Boston in 2023 to provide an update on 3D model advancements, and how they can complement existing models to increase productivity and clinical relevancy to accelerate bench-to-bedside development for targeted patient populations and drug approvals.